Regulon: R-14
Regulons are regulatory units consisting of a coherently expressed set of genes and the associated regulator(s) whose binding site(s) they share.
Regulon Summary
Regulon summary table displays all associated information related to the specific regulon including the number of genes in the regulon, Hazard ratio, its Regulator, the Transcriptional Program that includes the regulon, Drugs that are associated with members of the regulon, together with mechanism of action and class, and enriched hallmarks of cancer if any.
| Genes | Cox Hazard Ratio | Regulators | Causal Flows | Transcriptional Programs | Hallmarks |
|---|---|---|---|---|---|
| 101 | -0.650651 | 1 | 0 | Pr-83 |           |
Regulon Genes
List of genes that are included in the regulon. These genes have similar expression profiles in subset of patients and they share common binding motif for the Regulator of the regulon. Clicking on the gene name will take you to the gene specific page with more details. Please wait while information is collated from several resources after you click.
Regulon Drugs
| Name | Approved Symbol | Type | Action Type | Mechanism of Action | Max Trial Phase | Max GBM Phase |
|---|---|---|---|---|---|---|
| SCH-708980 | IL10 | Antibody | INHIBITOR | Interleukin-10 inhibitor | 2 | 0 |
| ELX-02 | RPS6 | Unknown | MODULATOR | 80S Ribosome modulator | 2 | 0 |
| ATALUREN | RPS6 | Small molecule | MODULATOR | 80S Ribosome modulator | 4 | 0 |
| OPROZOMIB | PSMD1 | Small molecule | INHIBITOR | 26S proteosome inhibitor | 1 | 0 |
| IXAZOMIB | PSMD1 | Small molecule | INHIBITOR | 26S proteasome inhibitor | 4 | 0 |
| LONAFARNIB | FNTA | Small molecule | INHIBITOR | Protein farnesyltransferase inhibitor | 4 | 1 |
| MARIZOMIB | PSMB2 | Small molecule | INHIBITOR | 20S proteosome inhibitor | 3 | 3 |
| MT-3724 | RPS6 | Unknown | BINDING AGENT | B-lymphocyte antigen CD20 binding agent | 2 | 0 |
| METFORMIN | GPD2 | Small molecule | INHIBITOR | Mitochondrial complex I (NADH dehydrogenase) inhibitor | 4 | 2 |
| METFORMIN HYDROCHLORIDE | GPD2 | Small molecule | INHIBITOR | Mitochondrial complex I (NADH dehydrogenase) inhibitor | 4 | 0 |
| TIPIFARNIB | FNTA | Small molecule | INHIBITOR | Protein farnesyltransferase inhibitor | 3 | 2 |
| BORTEZOMIB | PSMD1 | Small molecule | INHIBITOR | 26S proteosome inhibitor | 4 | 1 |
| ME-344 | NDUFA4 | Small molecule | INHIBITOR | Mitochondrial complex I (NADH dehydrogenase) inhibitor | 1 | 0 |
| IXAZOMIB CITRATE | PSMD1 | Small molecule | INHIBITOR | 26S proteosome inhibitor | 4 | 0 |
| FGI-101-1A6 | TSG101 | Antibody | INHIBITOR | Tumor susceptibility gene 101 protein inhibitor | 1 | 0 |
| CARFILZOMIB | PSMD1 | Protein | INHIBITOR | 26S proteosome inhibitor | 4 | 0 |
Causal Flows
Causal Flows are statistically significant links between putative causal events (somatic mutations, copy number variations, chromosomal translocations, etc.) and the activity levels of regulators and regulons. In the causal flow a mutation may causally activates or deactivates a downstream regulator which then might up- or down-regulates a regulon that contains genes with similar expression profiles and binding sites.
Causal Mechanistic Flows for Regulon R-14
| ID | Mutation | Role | Regulator | Role | Regulon | # downstream regulons | # diffexp regulons | Drugs |
|---|